Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
MOUNTAIN Study did not meet primary endpoint at Day 15 Statistical significance on HAM-D scale achieved at Days 3, 8 and 12; preliminary data from long-term follow-up suggest maintenance of effect on depressive symptoms Statistical significance achieved at Days 3, 8, 12 and 15 in patients with
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2019-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, December 2,
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
ZULRESSO™ (brexanolone) CIV injection revenues of $1.5M in third quarter Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies with topline data expected in 4Q 2019 and 2020, respectively Planning to expand pipeline with two new GABA and NMDA clinical-stage assets Conference call
View HTML
Toggle Summary Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 11, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on November 1, 2019 , the
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 9, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on October 1, 2019 ,
View HTML
Toggle Summary Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series
  Enrollment complete in the Phase 3 MOUNTAIN Study evaluating SAGE-217 in the treatment of major depressive disorder (MDD); topline results expected in 4Q 2019     CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on September 3, 2019 ,
View HTML
Toggle Summary Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder
Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points SAGE-217 is currently being investigated in the Phase 3 MOUNTAIN trial for the treatment of MDD, with
View HTML